Effects of progestin-only contraceptives on the endometrium

References

• Bastianelli C, Farris M, Bruni V, et al. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 4. Effects on uterine and cervical epithelia. Expert Rev Clin Pharmacol. 2020;13:163–182.
   PubMed Web of Science ®Google Scholar
• Garcia CR, Pincus G, Rock J. Effects of three 19-nor steroids on human ovulation and menstruation. Am J Obstet Gynecol. 1958;75:82–97.
   PubMed Web of Science ®Google Scholar
• Djerassi C. The history of progestins. In: Benagiano G, Diczfalusy E, Zulli P, editors. Progestogens in Therapy. New York: Raven Press; 1983. pp. 1-12.
   Google Scholar
• Siegel I. Conception control by long-acting progestogens: preliminary report. Obstet Gynecol. 1963;21:666–668.
   PubMed Web of Science ®Google Scholar
• Coutinho EM, de Souza JC, Csapo AI. Reversible sterility induced by medroxyprogesterone injection. Fertil Steril. 1966;17:261–266.
   PubMed Web of Science ®Google Scholar
• Zañartu J, Rice-Wray E, Goldzieher JW. Fertility control with long-acting injectable steroids. Obstet Gynecol. 1966;28:513–515.
   PubMed Web of Science ®Google Scholar
• Toppozada HK, Koetsawang S, Aimakhu VE, et al. Multinational Comparative Clinical Trial of Long-Acting Injectable Contraceptives: norethisterone Enanthate Given in Two Dosage Regimens and Depot-Medroxyprogesterone Acetate. Final Report. Contraception. 1983;28:1–20.
   PubMed Web of Science ®Google Scholar
• Pharriss BB, Erickson R, Bashaw J, et al. Progestasert: a uterine therapeutic system for long-term contraception: I. Philosophy and clinical efficacy. Fertil Steril. 1974;25:915–921.
   PubMed Web of Science ®Google Scholar
• Luukkainen T, Allonen H, Haukkamaa M, et al. Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study. Contraception. 1987;36:169–179.
   PubMed Web of Science ®Google Scholar
• Croxatto H, Díaz S, Vera R, et al. Fertility control in women with a progestogen released in microquantities from subcutaneous capsules. Am J Obstet Gynecol. 1969;105:1135–1138.
   PubMed Web of Science ®Google Scholar
• Croxatto H. Clinical profile of implanon: a single-rod etonogestrel contraceptive implant. Eur J Contracept Reprod Health Care. 2000;5(Suppl):21–28.
   PubMedGoogle Scholar
• Nuttal ID, Elstein M. Steroid releasing vaginal rings. Acta Eur Fertil. 1980;11:225–230.
   PubMedGoogle Scholar
• Regidor PA. Clinical relevance in present day hormonalcontraception. Horm Mol Biol Clin Investig. 2018;37:1.
   Web of Science ®Google Scholar
• Levy D, Christin-Maitre S, Leroy I, et al. The Endometrial Approach in Contraception. Ann N Y Acad Sci. 1997;828:59–83.
   PubMed Web of Science ®Google Scholar
• Africander DJ Comparative study of the molecular mechanism of action of the synthetic progestins, Medroxyprogesterone acetate and Norethisterone acetate. Dissertation presented in fulfilment of the requirements for the degree PhD in Biochemistry. Stellenbosch, South Africa: Stellenbosch University Press; 2010.
   Google Scholar
• Skosanaa SB, Woodlanda JG, Cartwright M, et al. Differential metabolism of clinically-relevant progestogens in cell lines and tissue: implications for biological mechanisms. J Steroid Biochem Mol Biol. 2019;189:145–153.
   PubMed Web of Science ®Google Scholar
• Louw-du Toit R, Hapgood JP, Africander D. A direct comparison of the transcriptional activities of progestins used in contraception and menopausal hormone therapy via the mineralocorticoid receptor. Biochem Biophys Res Commun. 2020;526:466–471.
   PubMed Web of Science ®Google Scholar
• Houshdaran S, Chen JC, Vallvé-Juanico J, et al. Progestins Related to Progesterone and Testosterone Elicit Divergent Human Endometrial Transcriptomes and Biofunctions. Int J Mol Sci. 2020;21:2625.
   Web of Science ®Google Scholar
• Salamonsen LA, Kovacs GT, Findlay JK. Current concepts of the mechanisms of menstruation. Baillieres Best Pract Res Clin Obstet Gynaecol. 1999;13:161–179.
   PubMed Web of Science ®Google Scholar
• Deneris A. PALM-COEIN Nomenclature for Abnormal Uterine Bleeding. J Midwifery Womens Health. 2016;61:376–379.
   PubMed Web of Science ®Google Scholar
• Munro MG, Critchley HO, Fraser IS. FIGO Menstrual Disorders Working Group. The FIGO classification of causes of abnormal uterine bleeding in the reproductive years. Fertil Steril. 2011;95:2204–8, 2208.e1-3.
   PubMed Web of Science ®Google Scholar
• Lockwood CJ, Krikun G, Hausknecht V, et al. Decidual Cell Regulation of Hemostasis During Implantation and Menstruation. Ann N Y Acad Sci. 1997;828:188–193.
   PubMed Web of Science ®Google Scholar
• Lockwood CJ, Krikun G, Hausknecht VA, et al. Matrix Metalloproteinase and Matrix Metalloproteinase Inhibitor Expression in Endometrial Stromal Cells During Progestin-Initiated Decidualization and Menstruation-Related Progestin Withdrawal. Endocrinology. 1998;139:4607–4613.
   PubMed Web of Science ®Google Scholar
• Galant C, Vekemans M, Lemoine P, et al. Temporal and spatial association of matrix metalloproteinases with focal endometrial breakdown and bleeding upon progestin-only contraception. J Clin Endocrinol Metab. 2000;85:4827–4834.
   PubMed Web of Science ®Google Scholar
• Prifti S, Lelle I, Zhong G, et al. Matrix Metalloproteinase 2 and Tissue Inhibitor of Metalloproteinase 2 Expression Is Not Regulated by Norgestimate or Norelgestromin. Gynecol Endocrinol. 2004;18:23–27.
   PubMed Web of Science ®Google Scholar
• Krikun G, Critchley H, Schatz F, et al. Abnormal Uterine Bleeding During Progestin-Only Contraception May Result From Free Radical-Induced Alterations in Angiopoietin Expression. Am J Pathol. 2002;161:979–986.
   PubMed Web of Science ®Google Scholar
• Krikun G, Sakkas D, Schatz F, et al. Endometrial angiopoietin expression and modulation by thrombin and steroid hormones: a mechanism for abnormal angiogenesis following long-term progestin-only contraception. Am J Pathol. 2004;164:2101–2107.
   PubMed Web of Science ®Google Scholar
• Shapiro JP, Guzeloglu-Kayisli O, Kayisli UA, et al. Thrombin impairs human endometrial endothelial angiogenesis; implications for progestin-only contraceptive-induced abnormal uterine bleeding. Contraception. 2017;95:592–601.
   PubMed Web of Science ®Google Scholar
• Lockwood CJ, Kumar P, Krikun G, et al. Effects of Thrombin, Hypoxia, and Steroids on interleukin-8 Expression in Decidualized Human Endometrial Stromal Cells: implications for Long-Term Progestin-Only Contraceptive-Induced Bleeding. J Clin Endocrinol Metab. 2004;89:1467–1475.
   PubMed Web of Science ®Google Scholar
• Lockwood CJ, Schatz F, Krikun G. Angiogenic factors and the endometrium following long term progestin only contraception. Histol Histopathol. 2004;19:167–172.
   PubMed Web of Science ®Google Scholar
• Guzeloglu-Kayisli O, Basar M, Shapiro JP, et al. Long-acting Progestin-Only Contraceptives Enhance Human Endometrial Stromal Cell Expressed Neuronal pentraxin-1 and Reactive Oxygen Species to Promote Endothelial Cell Apoptosis. J Clin Endocrinol Metab. 2014;99:E1957–66.
   PubMed Web of Science ®Google Scholar
• Guzeloglu Kayisli O, Kayisli UA, Basar M, et al. Progestins Upregulate FKBP51 Expression in Human Endometrial Stromal Cells to Induce Functional Progesterone and Glucocorticoid Withdrawal: implications for Contraceptive- Associated Abnormal Uterine Bleeding. PLoS One. 2015;10:e0137855.
   PubMed Web of Science ®Google Scholar
• Monds RE. Pseudomalignant endometrial changes induced by administration ofnew synthetic progestins. Proc Mayo Clin. 1959;34:321–81959.
   PubMed Web of Science ®Google Scholar
• Martinez-Manautou J, Maqueo M, Gilbert RA, et al. Human endometrial activity of several new derivatives of 17-acetoxyprogesterone. Fertil Steril. 1962;13:169–183.
   PubMed Web of Science ®Google Scholar
• Maqueo M, Perez-Vega E, Goldzieher JW, et al. Comparison of the endometrial activity of 3 synthetic progestins used in fertility control. Amer J Obstet Gynecol. 1963;85:427–432.
   PubMed Web of Science ®Google Scholar
• Rice-Wray E, Aranda-Rosell A, Maqueo M, et al. Comparison of the long-term endometrial effects of synthetic progestins used in fertility control. Amer J Obstet Gynecol. 1963;87:429–433.
   PubMed Web of Science ®Google Scholar
• Martinez-Manautou J, Cortez V, Giner J, et al. Low Doses of Progestogen as an Approach to Fertility Control. Fertil Steril. 1966;17:49–57.
   PubMed Web of Science ®Google Scholar
• Martinez-Manautou J. Continuous low dose progestagen for contraception. IPPF Med Bull. 1968;2:2–3.
   PubMedGoogle Scholar
• Mears E, Vessey MP, Andolsek L, et al. Preliminary Evaluation of Four Oral Contraceptives Containing Only Progestogens. Br Med J. 1969;2(5659):730–734.
   PubMedGoogle Scholar
• Aref I, Hefnawi T, Kandil O, et al. Effect of Minipills on Physiologic Responses of Human Cervical Mucus, Endometrium, and Ovary. Fertil Steril. 1973;24:578–583.
   PubMed Web of Science ®Google Scholar
• Ludwig H. The morphologic response of the human endometrium to long-term treatment with progestational agents. Am J Obstet Gynecol. 1982;142:796–808.
   PubMed Web of Science ®Google Scholar
• Dinh A, Sriprasert I, Williams AR, et al. A review of the endometrial histologic effects of progestins and progesterone receptor modulators in reproductive age women. Contraception. 2015;91:360–367.
   PubMed Web of Science ®Google Scholar
• Hourihan HM, Sheppard BL, Bonnar J. A Morphometric Study of the Effect of Oral Norethisterone or Levonorgestrel on Endometrial Blood Vessels. Contraception. 1986;34:603–612.
   PubMed Web of Science ®Google Scholar
• Landgren BM, Dada O, Aedo A-R, et al. Pituitary, ovarian and endometrial effects of 300 μg norethisterone and 30 μg levonorgestrel administered on cycle days 7 to 10. Contraception. 1990;41:569–581.
   PubMed Web of Science ®Google Scholar
• Kühne D, Seidl S, Göretzlehner G. Contraceptive Treatment with Chlormadinone and its Effect on the Endometrium. A Histological Investigation. Endokrinologie. 1972;59:295–306.
   PubMedGoogle Scholar
• Benagiano G, Bastianelli C, Farris M. Hormonal contraception: state of the art and future perspectives. Minerva Ginecol. 2007;59:241–270.
   PubMedGoogle Scholar
• Hanjalic-Beck A, Schäfer WR, Deppert WR, et al. Chlormadinone Acetate Suppresses Prostaglandin Biosynthesis in Human Endometrial Explants. Fertil Steril. 2012;98:1017–1022.
   PubMed Web of Science ®Google Scholar
• Haimovich S, Mancebo G, Alameda F, et al. Endometrial preparation with desogestrel before Essure hysteroscopic sterilization: preliminary study. J Minim Invasive Gynecol. 2013;20:591–594.
   PubMed Web of Science ®Google Scholar
• Palacios S, Colli E, Regidor P-A. Multicenter, Phase III Trials on the Contraceptive Efficacy, Tolerability and Safety of a New Drospirenone-Only Pill. Acta Obstet Gynecol Scand. 2019;98:1549–1557.
   PubMed Web of Science ®Google Scholar
• David SS, Huggins GR, Garcia CR, et al. A synthetic steroid (R2323) as a once-a-week oral contraceptive. Fertil Steril. 1979;31:278–281.
   PubMed Web of Science ®Google Scholar
• Okada H, Nakajima T, Yoshimura T, et al. The Inhibitory Effect of Dienogest, a Synthetic Steroid, on the Growth of Human Endometrial Stromal Cells in Vitro. Mol Hum Reprod. 2001;7:341–347.
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Takeuchi T, Mita S, et al. Dienogest, a Synthetic Progestin, Inhibits the Proliferation of Immortalized Human Endometrial Epithelial Cells With Suppression of Cyclin D1 Gene Expression. Mol Hum Reprod. 2009;15:693–701.
   PubMed Web of Science ®Google Scholar
• Benagiano G, Gabelnick H, Brosens I. Long-Acting Hormonal Contraception. Women’s Health (Lond Engl). 2015;11:749–757.
   PubMedGoogle Scholar
• Harun-Ar-Rashid BMA, Choudhury SA. Effects of Long-Acting Steroid Contraceptives on Ovarian and Uterine Histology of Rats. Bangladesh Med Res Counc Bull. 1977;3:46–51.
   PubMedGoogle Scholar
• Bhowmik T, Mukherjee M. Histological Changes in the Ovary and Uterus of Rat After Injectable Contraceptive Therapy. Contraception. 1988;37:529–538.
   PubMed Web of Science ®Google Scholar
• Lee RA. Contraceptive and Endometrial Effects of Medroxyprogesterone Acetate. Am J Obstet Gynecol. 1969;104:130–133.
   PubMed Web of Science ®Google Scholar
• Maqueo M, Godorovsky J, Rice-Wray E, et al. Endometrial changes in women usign hormonal contraceptives for periods up to ten years. Contraception. 1970;1:15–29.
   Google Scholar
• Kamal EM, Hafez AM. Effect of copper intrauterine device vs. injectable contraceptive on serum hormone levels and cell mitotic activity in endometrium. Middle East Fertil Soc J. 2013;18:142–146.
   Google Scholar
• Schwallie PC, Assenzo JR. Contraceptive use-efficacy study utilizing medroxprogesterone acetate administered as an intramuscular injection every 90 days. Fertil Steril. 1973;24:331–339.
   PubMed Web of Science ®Google Scholar
• Gopalkrishnan K, Virkar KD. Cervical cytology and endometrial biopsy in women using long acting injectable progesterone (DMPA) - a preliminary report. Indian J Med Res. 1980;71:372–374.
   PubMed Web of Science ®Google Scholar
• Thurman AR, Soper DE. Endometrial histology of depo-medroxyprogesterone acetate users: a pilot study. Infect Dis Obstet Gynecol. 2006;art. no:69402.
   Google Scholar
• Smith-McCune KK, Hilton JF, Shanmugasundaram U, et al. Effects of depot-medroxyprogesterone acetate on the immune microenvironment of the human cervix and endometrium: implications for HIV susceptibility. Mucosal Immunol. 2017;10:1270–1278.
   PubMed Web of Science ®Google Scholar
• Courtin A, Communal L, Vilasco M, et al. Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells. Breast Cancer Res Treat. 2012;131:49–63.
   PubMed Web of Science ®Google Scholar
• Sereepapong W, Chotnopparatpattara P, Taneepanichskul S, et al. Endometrial progesterone and estrogen receptors and bleeding disturbances in depot medroxyprogesterone acetate users. Hum Reprod. 2004;19:547–552.
   PubMed Web of Science ®Google Scholar
• Simbar M, Tehrani FR, Hashemi Z, et al. A comparative study of Cyclofem® and depot medroxyprogesterone acetate (DMPA) effects on endometrial vasculature. J Fam Plann Reprod Health Care. 2007;33:271–276.
   PubMed Web of Science ®Google Scholar
• Dane B, Akca A, Dane C, et al. Comparison of the effects of the levonorgestrel-releasing intrauterine system (Mirena®) and depot-medroxyprogesterone acetate (Depo-Provera®) on subendometrial micro-vascularisation and uterine artery blood flow. Eur J Contracept Reprod Health Care. 2009;14:240–244.
   PubMed Web of Science ®Google Scholar
• Vincent AJ, Salamonsen LA. The role of matrix metalloproteinases and leukocytes in abnormal uterine bleeding associated with progestin-only contraceptives. Hum Reprod. 2000;15(Suppl. 3):135–143.
   PubMedGoogle Scholar
• Vincent AJ, Zhang J, Östör A, et al. Decreased tissue inhibitor of metalloproteinase in the endometrium of women using depot medroxyprogesterone acetate: a role for altered endometrial matrix metalloproteinase/tissue inhibitor of metalloproteinase balance in the pathogenesis of abnormal uterine bleeding? Hum Reprod. 2002;17:1189–1198.
   PubMed Web of Science ®Google Scholar
• Larrañaga A, Kesseru E. Dos años de experiencia clinica con el enantato de noetisterona como contraceptivo inyeactable de deposito [Two years of clinical experience with the depot injectable contraceptive norethisterone enanthate]. Gynecol Obstet (Peru). 1968;14:209–221.
   Google Scholar
• Achari K. Effect of nor-ethisterone enanthate (SH 393) on the structure of the endometrium and on the cervical mucus. J Obstet Gynaecol India. 1969;19:731–736.
   PubMedGoogle Scholar
• Benagiano G, Hingorani V, Fotherby K, et al. Return of ovarian function and endometrial morphology in women treated with norethisterone oenanthate: a pilot study. Fertil Steril. 1980;34:456–460.
   PubMed Web of Science ®Google Scholar
• Zalányi S, Landgren BM, Johannisson E. Pharmacokinetics, pharmacodynamic and endometrial effects of a single dose of 200 mg norethisterone enanthate. Contraception. 1984;30:225–237.
   PubMed Web of Science ®Google Scholar
• Chaudhuri C, Dutta SK, Mukherjee M. Effect of Norethisterone Enanthate on the Blood Count and Endometrial Histology of Indian Women. Contraception. 1985;32:417–428.
   PubMed Web of Science ®Google Scholar
• Chinvanthananond P. Endometrial Pattern in Long-Term Users of NET-EN. J Med Assoc Thai. 1993;76:385–387.
   PubMedGoogle Scholar
• Wonodirekso S, Hadisaputra W, Affandi B, et al. Cytokeratin 8, 18 and 19 in Endometrial Epithelium of Norplant and Norethisterone Enanthate Injectable Progestogen Contraceptive Users. Hum Reprod. 1996;11(Suppl 2):144–149.
   PubMedGoogle Scholar
• Wonodirekso S, Affandi B, Siregar B, et al. Endometrial Epithelial Integrity and Subepithelial Reticular Fibre Expression in Progestin Contraceptive Acceptors. Hum Reprod. 2000;15(Suppl 3):189–196.
   PubMedGoogle Scholar
• Scommegna A, Pandya GN, Christ M, et al. Intrauterine Administration of Progesterone by a Slow Releasing Device. Fertil Steril. 1970;21:201–210.
   PubMed Web of Science ®Google Scholar
• Scommegna A, Ilekis J, Rao R, et al. Endometrial Prostaglandin F Content in Women Wearing Non-medicated or Progestin-Releasing Intrauterine Devices. Fertil Steril. 1978;29:500–504.
   PubMedGoogle Scholar
• Nilsson CG, Johansson ED, Jackanicz TM, et al. Biodegradable Polylactate as a Steroid-Releasing Polymer: intrauterine Administration of D-Norgestrel. Am J Obstet Gynecol. 1975;122:90–95.
   PubMed Web of Science ®Google Scholar
• Sievers S, Dallenbach-Hellweg G. Klnische und morphoIogische unteruchungen bei patientinnen nach einlage eines gestagenhaltigen intrauterinpessars (Progestasert system) [Clinical and Morphological Studies in Patients With a Progesterone-Releasing Intrauterine Contraceptive Device (Progestasert-System)]. Geburtshilfe Frauenheilkd. 1976;36:334–340.
   PubMedGoogle Scholar
• Wan LS, Hsu YC, Ganguly M, et al. Effects of the Progestasert on the menstrual pattern, ovarian steroids and endometrium. Contraception. 1977;16:417–434.
   PubMed Web of Science ®Google Scholar
• Hagenfeldt K, Landgren BM, Edström K, et al. Biochemical and Morphological Changes in the Human Endometrium Induced by the Progestasert Device. Contraception. 1977;16:183–197.
   PubMed Web of Science ®Google Scholar
• Liedholm P, Sjöberg NO, Srivastava K, et al. No Increase of the Fibrinolytic Activity of the Human Endometrium by Progesterone-Releasing IUD (ProgestasertR). Contraception. 1978;17:531–536.
   Web of Science ®Google Scholar
• Shaw ST Jr, Macaulay LK, Aznar R, et al. Effects of a progesterone-releasing intrauterine contraceptive device on endometrial blood vessels: a morphometric study. Am J Obstet Gynecol. 1981;141:821–827.
   PubMed Web of Science ®Google Scholar
• Sheppard BL. Endometrial morphological changes in IUD users: A REVIEW. Contraception. 1987;36:1–10.
   PubMed Web of Science ®Google Scholar
• Sheppard BL, Bonnar J. The effect of the progesterone-releasing intrauterine device on uterine endometrium and fallopian tube epithelium. Arch Toxicol Suppl. 1982;5:231–234.
   PubMedGoogle Scholar
• Sheppard BL, Bonnar J. The effects of intrauterine contraceptive devices on the ultrastructure of the endometrium in relation to bleeding complications. Am J Obstet Gynecol. 1983;146:829–839.
   PubMed Web of Science ®Google Scholar
• Ermini M, Carpino F, Petrozza V, et al. Distribution and effect on the endometrium of progesterone released from a progestasert device. Hum Reprod. 1989;4:221–228.
   PubMed Web of Science ®Google Scholar
• Snowden R. The progestasert and ectopic pregnancy. Br Med J. 1977;2:1600–1601.
   PubMedGoogle Scholar
• Tatum HJ, Connell EB. A decade of intrauterine contraception: 1976-1986. Fertil Steril. 1986;46:171–192.
   Web of Science ®Google Scholar
• Nilsson CG, Johansson ED, Jackanicz TM, et al. Biodegradable polylactate as a steroid-releasing polymer: intrauterine administration of D-norgestrel. Am J Obstet Gynecol. 1975;122:90–95.
   PubMed Web of Science ®Google Scholar
• Apter D, Gemzell-Danielsson K, Hauck B, et al. Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies. Fertil Steril. 2014;101:1656-1662.
   Web of Science ®Google Scholar
• Nilsson CG, Luukkainen T, Arko H. Endometrial morphology of women using a D-norgestrel-releasing intrauterine device. Fertil Steril. 1978;29:397–401.
   PubMed Web of Science ®Google Scholar
• Silverberg SG, Haukkamaa M, Arko H, et al. Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices. Int J Gynecol Pathol. 1986;5:235–241.
   PubMed Web of Science ®Google Scholar
• Critchley HO, Wang H, Jones RL, et al. Morphological and functional features of endometrial decidualization following long-term intrauterine levonorgestrel delivery. Hum Reprod. 1998;13:1218–1224.
   PubMed Web of Science ®Google Scholar
• Phillips V, Graham CT, Manek S, et al. The effects of the levonorgestrel intrauterine system (mirena coil) on endometrial morphology. J Clin Pathol. 2003;56:305–307.
   PubMed Web of Science ®Google Scholar
• Hejmadi RK, Chaudhri S, Ganesan R, et al. Morphologic changes in the endometrium associated with the use of the mirena coil: a retrospective study of 106 cases. Int J Surg Pathol. 2007;15:148–154.
   Web of Science ®Google Scholar
• Hidalgo MM, Hidalgo-Regina C, Bahamondes MV, et al. Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system. Contraception. 2009;80:84–89.
   PubMed Web of Science ®Google Scholar
• Coloma F, Muñoz M, Costa S, et al. Endometrial hysteroscopic morphologic pattern associated with levonorgestrel intrauterine device. Rev Iberoamer Fertil Reprod Hum. 2005;22:39–44.
   Google Scholar
• Chai M, Su S, Dong B. Morphological and Ultrastructural Changes in Human Endometrium Following Low-Dose Levonorgestrel Contraceptive Intrauterine Systems (LNG-IUS-12) 13.5 mg. J Obstet Gynecol India. 2015;5:323–327.
   Google Scholar
• Rutanen E-M, Salmi A, Nyman T. mRNA expression of insulin-like growth factor-I (IGF-I) is suppressed and those of IGF-II and IGF-binding protein-1 are constantly expressed in the endometrium during use of an intrauterine levonorgestrel system. Mol Hum Reprod. 1997;3:749–754.
   PubMed Web of Science ®Google Scholar
• Rutanen E-M. Insulin-like growth factors and insulin-like growth factor binding proteins in the endometrium. Effect of intrauterine levonorgestrel delivery. Hum Reprod. 2000;15(Suppl. 3):173–181.
   PubMedGoogle Scholar
• Salmi A, Pakarinen P, Peltola A-M, et al. The effect of intrauterine levonorgestrel use on the expression of c- JUN, oestrogen receptors, progesterone receptors and Ki-67 in human endometrium. Mol Hum Reprod. 1998;4:1110–1115.
   PubMed Web of Science ®Google Scholar
• Critchley HOD, Wang H, Kelly RW, et al. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system. Hum Reprod. 1998;13:1210–1217.
   PubMed Web of Science ®Google Scholar
• Jones RL, Critchley HOD. Morphological and functional changes in human endometrium following intrauterine levonorgestrel delivery. Hum Reprod. 2000;15:162–172.
   PubMed Web of Science ®Google Scholar
• Engemise SL, Willets JM, Taylor AH, et al. Changes in glandular and stromal estrogen and progesterone receptor isoform expression in eutopic and ectopic endometrium following treatment with the levonorgestrel-releasing intrauterine system. Eur J Obstet Gynecol Reprod Biol. 2011;157:101–106.
   PubMed Web of Science ®Google Scholar
• Zhu P, Liu X, Luo H, et al. The Effect of Levonorgestrel-Releasing Intrauterine Device (20 Micrograms/Day) (LNG-IUD-20) on the Morphological Structure of Human Endometrium: A Study of the Endometrial Factor VIII Activity in the Women Before and After Insertion of LNG-IUD-20 by the Digital Image Analysis. Contraception. 1995;52:63–68.
   PubMed Web of Science ®Google Scholar
• Pakrashi T, Taylor JL, Nelson A, et al. The Effect of Levonorgestrel on Fibrinolytic Factors in Human Endometrial Endothelial Cells. Reprod Sci. 2016;23:1536–1541.
   PubMed Web of Science ®Google Scholar
• Skinner JL, Riley SC, Gebbie AE, et al. Regulation of matrix metalloproteinase-9 in endometrium during the menstrual cycle and following administration of intrauterine levonorgestrel. Hum Reprod. 1999;14:793–799.
   PubMed Web of Science ®Google Scholar
• Labied S, Galant C, Nisolle M, et al. Differential elevation of matrix metalloproteinase expression in women exposed to levonorgestrel-releasing intrauterine system for a short or prolonged period of time. Hum Reprod. 2009;24:113–121.
   PubMed Web of Science ®Google Scholar
• Jones RL, Salamonsen LA, Critchley HOD, et al. Inhibin and activin subunits are differentially expressed in endometrial cells and leukocytes during the menstrual cycle, in early pregnancy and in women using progestin-only contraception. Mol Hum Reprod. 2000;6:1107–1117.
   PubMed Web of Science ®Google Scholar
• Maruo T, Laoag-Fernandez JB, Pakarinen P, et al. Effects of the Levonorgestrel-Releasing Intrauterine System on Proliferation and Apoptosis in the Endometrium. Hum Reprod. 2001;16:2103–2108.
   PubMed Web of Science ®Google Scholar
• Mandelin E, Koistinen H, Koistinen R, et al. Endometrial Expression of Glycodelin in Women With Levonorgestrel-Releasing Subdermal Implants. Fertil Steril. 2001;76:474–478.
   PubMed Web of Science ®Google Scholar
• Peloggia A, Petta CA, Bahamondes L, et al. Endometrial chemokines, uterine natural killer cells and mast cells in long-term users of the levonorgestrel-releasing intrauterine system. Hum Reprod. 2006;21:1129–1134.
   PubMed Web of Science ®Google Scholar
• McGavigan CJ, Dockery P, Metaxa-Mariatou V, et al. Hormonally mediated disturbance of angiogenesis in the human endometrium after exposure to intrauterine levonorgestrel. Hum Reprod. 2003;18:77–84.
   PubMed Web of Science ®Google Scholar
• Jondet M, Letellier B, Verdys M-T. Endometrial vascularization in levonorgestrel intrauterine device users; computerized microvessel measurement study. Contraception. 2005;71:60–64.
   PubMed Web of Science ®Google Scholar
• Stéphanie R, Labied S, Blacher S, et al. Endometrial vessel maturation in women exposed to levonorgestrel-releasing intrauterine system for a short or prolonged period of time. Hum Reprod. 2007;22:3084–3091.
   PubMed Web of Science ®Google Scholar
• Zalel Y, Shulman A, Lidor A, et al. The Local Progestational Effect of the Levonorgestrel-Releasing Intrauterine System: A Sonographic and Doppler Flow Study. Hum Reprod. 2002;17:2878–2880.
   PubMed Web of Science ®Google Scholar
• Bastianelli C, Farris M, Rapiti S, et al. Different bleeding patterns with the use of levonorgestrel intrauterine system: are they associated with changes in uterine artery blood flow? BioMed Res Internat. 2014;art. no:815127.
   Google Scholar
• Laoag-Fernandez JB, Maruo T, Pakarinen P, et al. Effects of levonorgestrel-releasing intra-uterine system on the expression of vascular endothelial growth factor and adrenomedullin in the endometrium in adenomyosis. Hum Reprod. 2003;18:694–699.
   PubMed Web of Science ®Google Scholar
• Roopa BA, Loganath A, Singh K. The effect of a levonorgestrel-releasing intrauterine system on angiogenic growth factors in the endometrium. Hum Reprod. 2003;18:1809–1819.
   PubMed Web of Science ®Google Scholar
• Möller B, Rönnerdag M, Wang G, et al. Expression of vascular endothelial growth factors and their receptors in human endometrium from women experiencing abnormal bleeding patterns after prolonged use of a levonorgestrel-releasing intrauterine system. Hum Reprod. 2005;20:1410–1417.
   PubMed Web of Science ®Google Scholar
• Charlton F, Otton G, Hedges A, et al. Endometrial Granulomas with Levonorgestrel Intrauterine System (Mirena). Pathology. 2014;46:457–458.
   PubMed Web of Science ®Google Scholar
• Stewart CRJ, Leake R. Endometrial Synovial-like Metaplasia Associated With Levonorgestrel-releasing Intrauterine System. Int J Gynecol Pathol. 2015;34:570–575.
   PubMed Web of Science ®Google Scholar
• Sinha A, Nwosu EC. Endometrial Polyp and the Levonorgestrel Intrauterine System–A Case Report and Literature Review. J Obstet Gynaecol. 2002;22:695.
   PubMedGoogle Scholar
• Shanmugasundaram U, Hilton JF, Critchfield JW, et al. Effects of the Levonorgestrel-Releasing Intrauterine Device on the Immune Microenvironment of the Human Cervix and Endometrium. Am J Reprod Immunol. 2016;76:137–148.
   PubMed Web of Science ®Google Scholar
• Kim CR, Martinez-Maza O, Magpantay L, et al. Immunologic evaluation of the endometrium with a levonorgestrel intrauterine device in solid organ transplant women and healthy controls. Contraception. 2016;94:534–540.
   PubMed Web of Science ®Google Scholar
• Smith-McCune K, Thomas R, Averbach S, et al. Differential Effects of the Hormonal and Copper Intrauterine Device on the Endometrial Transcriptome. Sci Rep. 2020;10:6888.
   PubMed Web of Science ®Google Scholar
• Guttinger A, Critchley HOD. Endometrial effects of intrauterine levonorgestrel. Contraception. 2007;75(6 suppl):S93–S98.
   PubMed Web of Science ®Google Scholar
• Kincl FA, Benagiano G, Angee I. Diffusion of various steroids through polymer membranes. Steroids. 1968;11:673–680.
   PubMed Web of Science ®Google Scholar
• Sivin I, Campodonico I, Kiriwat O, et al. The performance of levonorgestrel rod and Norplant contraceptive implants: A 5-year randomized study. Hum Reprod. 1998;13:3371–3378.
   PubMed Web of Science ®Google Scholar
• Shaaban MM, Segal S, Salem HT, et al. Sonographic assessment of ovarian and endometrial changes during long- term Norplant use and their correlation with hormonal levels. Fertil Steril. 1993;59:998–1002.
   PubMed Web of Science ®Google Scholar
• Hadisaputra W, Affandi B, Witjaksono J, et al. Endometrial biopsy collection from women receiving Norplant®. Hum Reprod. 1996;11(Suppl. 2):31–34.
   PubMedGoogle Scholar
• Hadisaputra W, Affandi B, Rogers PAW. Endometrial biopsy collection from women receiving Norplant®. Med J Indonesia. 1998;7:25–28.
   Google Scholar
• Wang G, Zheng S, Fan Z. The changes of sex steroid receptors and morphology in Norplant treated endometrium. Zhonghua Fu Chan Ke Za Zhi. 1998;33:493–497.
   PubMedGoogle Scholar
• Critchley HOD, Bailey DA, Au CL, et al. Endocrinology: immunohistochemical sex steroid receptor distribution in endometrium from long-term subdermal levonorgestrel users and during the normal menstrual cycle. Hum Reprod. 1993;8:1632–1639.
   PubMed Web of Science ®Google Scholar
• Lau TM, Witjaksono J, Affandi B, et al. Expression of progesterone receptor mRNA in the endometrium during the normal menstrual cycle and in Norplant users. Hum Reprod. 1996;11:2629–2634.
   PubMed Web of Science ®Google Scholar
• Lau TM, Witjaksono J, Rogers PAW. Progesterone receptor in Norplant® endometrium. Hum Reprod. 1996;11(Suppl. 2):90–94.
   PubMedGoogle Scholar
• Toppozada MK, Ai-Sakkaf MK, Anwar MY, et al. Human endometrial nuclear estrogen receptors among Norplant® implant users. J Obstet Gynaecol. 1997;17:298–300.
   PubMedGoogle Scholar
• Hickey M, Salamonsen LA. Endometrial Structural and Inflammatory Changes With Exogenous Progestogens. Trends Endocrinol Metab. 2008;19:167–174.
   PubMed Web of Science ®Google Scholar
• Rogers PAW. Endometrial vasculature in Norplant® users. Hum Reprod. 1996;11(Suppl. 2):45–50.
   PubMedGoogle Scholar
• Wan LS. A review of the endometrial changes in Norplant® users. Ann NY Acad Sci. 1997;828:108–110.
   PubMed Web of Science ®Google Scholar
• Darney PD, Taylor RN, Klaisle C, et al. Serum concentrations of estradiol, progesterone, and levonorgestrel are not determinants of endometrial histology or abnormal bleeding in long-term Norplant® implant users. Contraception. 1996;53:97–100.
   PubMed Web of Science ®Google Scholar
• Faúndes A, Alvarez F, Brache V, et al. Endometrial thickness and oestradiol concentration in women with bleeding complaints during use of Norplant® implants. Hum Reprod. 1998;13:188–191.
   PubMed Web of Science ®Google Scholar
• Rogers PAW, Au CL, Contraception: AB. Endometrial microvascular density during the normal menstrual cycle and following exposure to long-term levonorgestrel. Hum Reprod. 1993;8:1396–1404.
   PubMed Web of Science ®Google Scholar
• Goodger AM, Rogers PAW, Affandi B. Contraception: endometrial endothelial cell proliferation in long-term users of subdermal levonorgestrel. Hum Reprod. 1994;9:1647–1651.
   PubMed Web of Science ®Google Scholar
• Palmer Marsh MM, Butt AR, Riley SC, et al. Immunolocalization of endothelin and neutral endopeptidase in the endometrium of users of subdermally implanted levonorgestrel (norplant®). Hum Reprod. 1995;10:2584–2589.
   PubMed Web of Science ®Google Scholar
• Palmer JA, Lau TM, Hickey M, et al. Immuno-histochemical study of endometrial microvascular basement membrane components in women using Norplant. Hum Reprod. 1996;11:2142–2150.
   PubMed Web of Science ®Google Scholar
• Marsh MM, Butt AR, Riley SC, et al. Immunolocalization of Endothelin and Neutral Endopeptidase in the Endometrium of Users of Subdermally Implanted Levonorgestrel (Norplant). Hum Reprod. 1995;10:2584–2589.
   PubMed Web of Science ®Google Scholar
• Hickey M, Simbar M, Young L, et al. A longitudinal study of changes in endometrial microvascular density in Norplant® implant users. Contraception. 1999;59:123–129.
   PubMed Web of Science ®Google Scholar
• Hickey M, Simbar M, Markham R, et al. Changes in vascular basement membrane in the endometrium of Norplant users. Hum Reprod. 1999;14:716–721.
   PubMed Web of Science ®Google Scholar
• Shi X, Han X, Weng J. Study on relationship between endometrium laminin expression and irregular uterine bleeding in Norplant users. Zhonghua Fu Chan Ke Za Zhi. 2000;35:169–171.
   PubMedGoogle Scholar
• Wonodirekso S, Au CL, Hadisaputrat W, et al. Cytokeratins 8, 18 and 19 in endometrial epithelial cells during the normal menstrual cycle and in women receiving Norplant®. Contraception. 1993;48:481–493.
   PubMed Web of Science ®Google Scholar
• Au CL, Affandi B, Rogers PAW. Immunohistochemical staining of von Willebrand factor in endometrium of women during the first year of Norplant®1 implants use. Contraception. 1994;50:477–489.
   PubMed Web of Science ®Google Scholar
• Lau TM, Affandi B, Rogers PAW. The effects of levonorgestrel implants on vascular endothelial growth factor expression in the endometrium. Mol Hum Reprod. 1999;5:57–63.
   PubMed Web of Science ®Google Scholar
• Hickey M, Fraser I, Dwarte D, et al. Endometrial vasculature in Norplant® users: preliminary results from a hysteroscopic study. Hum Reprod. 1996;11(SUPPL. 2):35–44.
   PubMedGoogle Scholar
• Runic R, Schatz F, Wan L, et al. Effects of Norplant on endometrial tissue factor expression and blood vessel structure. J Clin Endocrinol Metab. 2000;85:3853–3859.
   PubMed Web of Science ®Google Scholar
• Marbaix E, Vekemans M, Galant C, et al. A three-dimensional study of endometrial microvessels in women using the contraceptive subdermal levonorgestrel implant system, norplant®. Micron. 2004;35:589–595.
   PubMed Web of Science ®Google Scholar
• Hickey M, Carati C, Manconi F, et al. The measurement of endometrial perfusion in Norplant users: A pilot study. Hum Reprod. 2000;15:1086–1091.
   PubMed Web of Science ®Google Scholar
• Mascarenhas L, Van Beek A, Bennink HC, et al. A 2-year comparative study of endometrial histology and cervical cytology of contraceptive implant users in Birmingham, UK. Hum Reprod. 1998;13:3057–3060.
   PubMed Web of Science ®Google Scholar
• Croxatto HB, Mäkäräinen L. The Pharmacodynamics and Efficacy of Implanon. An overview of the data. Contraception. 1998;58(6 Suppl):91S–97S.
   PubMed Web of Science ®Google Scholar
• Varma R, Mascarenhas L. Endometrial effects of etonogestrel (Implanon) contraceptive implant. Curr Opin Obstet Gynecol. 2001;13:335–341.
   PubMed Web of Science ®Google Scholar
• Macpherson AM, Archer DF, Leslie S, et al. The effect of etonogestrel on VEGF, oestrogen and progesterone receptor immunoreactivity and endothelial cell number in human endometrium. Hum Reprod. 1999;14:3080–3087.
   PubMed Web of Science ®Google Scholar
• Charnock-Jones DS, Macpherson AM, Archer DF, et al. Effect of progestins on vascular endothelial growth factor, oestrogen receptor and progesterone receptor immunoreactivity and endothelial cell density in human endometrium. Hum Reprod. 2000;15(Suppl 3):85–95.
   PubMed Web of Science ®Google Scholar
• Wiese J, Marker IL, Holma P, et al. Long-term contraception with norethindrone subcutaneous capsules. Ann Clin Res. 1976;8:93–97.
   PubMedGoogle Scholar
• Massai MR, Díaz S, Quinteros E, et al. Contraceptive efficacy and clinical performance of nestorone implants in postpartum women. Contraception. 2001;64:369–376.
   PubMed Web of Science ®Google Scholar
• Landgren BM, Johannisson E, Masironi B, et al. Pharmacokinetic and pharmacodynamic investigations with vaginal devices releasing levonorgestrel at a constant, near zero order rate. Contraception. 1982;26:567–585.
   PubMed Web of Science ®Google Scholar
• Brache V, Mishell DR Jr., Lahteenmaki P, et al. Ovarian Function During Use of Vaginal Rings Delivering Three Different Doses of Nestorone. Contraception. 2001;63:257–261.
   PubMed Web of Science ®Google Scholar